Cargill wins EU novel foods approval for omega-6 form ARA

By Shane Starling

- Last updated on GMT

Related tags: Infant formula, European union, Docosahexaenoic acid

Cargill wins EU novel foods approval for omega-6 form ARA
Cargill is celebrating the European Union approval of a Mortierella alpine, algae fermented arachidonic acid (ARA)-rich oil, to be used in infant formula and formula for older children.

ARA is commonly found in such products in conjunction with omega-3 form, docosahexaenoic (DHA), and is found naturally in breast milk. Cargill’s version can now enter the infant formula supply dominated by DSM-Martek under the EU infant formula directive.

"Cargill is pleased that we now have the opportunity to help our European customers develop premium infant formulas using Cargill's ARA,"​ said David Henstrom, vice president of Cargill Health & Nutrition.

"This approval is the culmination of a series of regulatory efforts that, coupled with our increased capacity, now enables us to fulfill the needs of our infant formula customers in Europe."

The ingredient won generally recognised as safe (GRAS) approval from the Food and Drug Administration's (FDA) at the beginning of 2011.

The scientific literature points to brain and vision benefits for infants for ARA, although the European Food Safety Authority (EFSA) refused a claim for ARA and DHA that sought to state that, DHA and ARA, “contribute to the optimal brain development of infants and young children”.

Most infant formulas contain ARA to DHA ratios of about 2:1.

Cargill opened a Chinese facility in 2010 to boost its ARA production.

Claims

The rejected DHA-ARA claim in question was submitted by Merck Selbstmedikation GmbH in 2009 and followed global algae-sourced DHA leader, Martek Biosciences, which had a similar DHA-ARA dossier turned down in the first series of opinions in the second half of 2008.

The German firm recommended mothers consume 200mg of DHA per day during and after pregnancy to confer eye health and brain health benefits in the foetus and infant. But EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) said, “There is insufficient evidence to establish a cause and effect relationship.”

Related news

Show more

Related products

show more

Attract a new generation of omega-3 consumers

Attract a new generation of omega-3 consumers

DSM Nutritional Products | 15-Sep-2022 | Infographic

Want to bring your next omega-3 innovation to market quickly and sustainably? DSM's algal-sourced life's™OMEGA, enables you to get consumer-driven,...

Improve DOMS and Postexercise Lactate Accumulation

Improve DOMS and Postexercise Lactate Accumulation

Gencor-Pacific | 08-Sep-2022 | Clinical Study

Hydrocurc®’s clinical study suggests that a highly bioavailable curcumin may facilitate a quicker return to exercise training and/or allow a higher training...

DurOmega® Algal DHA 20% water dispersible powder

DurOmega® Algal DHA 20% water dispersible powder

INNOBIO Corporation Limited | 30-May-2022 | Technical / White Paper

INNOBIO most recently launched a new product DurOmega® Algal DHA 20% water dispersible powder with significantly reduced fishy odor and taste, which optimizes...

Total Solutions for Cognitive Health by Lubrizol

Total Solutions for Cognitive Health by Lubrizol

Lipofoods, a Lubrizol Company | 05-May-2022 | Technical / White Paper

Globally, health and wellbeing have shifted from a focus on physical health and nutrition to also include cognitive and mental wellness, therefore consumers...

Related suppliers

Follow us

Products

View more

Webinars